Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Prelude Therapeutics ( (PRLD) ).
Prelude Therapeutics announced that it has regained compliance with Nasdaq’s Minimum Bid Price Requirement as of September 18, 2025, after previously being notified of non-compliance on March 27, 2025. This resolution of compliance issues may positively impact the company’s market positioning and reassure stakeholders about its stock market standing.
The most recent analyst rating on (PRLD) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Prelude Therapeutics stock, see the PRLD Stock Forecast page.
Spark’s Take on PRLD Stock
According to Spark, TipRanks’ AI Analyst, PRLD is a Underperform.
Prelude Therapeutics faces significant financial hurdles due to ongoing losses and lack of revenue, which heavily impact its overall score. Technical analysis shows mixed short-term momentum, but long-term weakness persists. The valuation is challenged by a negative P/E ratio and lack of dividends. However, recent corporate developments, including promising clinical results and a solid cash runway, offer some positive aspects, albeit insufficient to offset the broader financial concerns.
To see Spark’s full report on PRLD stock, click here.
More about Prelude Therapeutics
Prelude Therapeutics Incorporated operates in the biotechnology industry, focusing on the development of innovative therapies for cancer treatment.
Average Trading Volume: 181,887
Technical Sentiment Signal: Sell
Current Market Cap: $58.86M
For detailed information about PRLD stock, go to TipRanks’ Stock Analysis page.